Geron, a biotechnology drugmaker, received FDA approval to try a therapy derived from human embryonic stem cells. This area is a novelty for both industry and the FDA and the approval of stem-cell therapy has been an ideological decision because the creation of the cells indicates the destruction of human embryos. For the approved study, which will last for at least one year, Geron will enroll paralyzed patients who can be treated within 14 days of their injury with injections of embryonic stem cells, differentiated into spinal-cord tissue, in the spine at the site of damage.